Cocrystal Pharma, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter report. Cocrystal is a clinical-stage antiviral biotechnology company; it has not generated revenue from product sales.
Business and pipeline
- CC-42344: Oral influenza A PB2 inhibitor. The filing reports Phase 2a human-challenge trial authorization and first-patient dosing in 2023, with topline results expected in 2024. An inhaled formulation remained in preclinical development, with a Phase 1 study being considered for 2024.
- CDI-988: Oral 3CL protease inhibitor being developed for coronavirus and norovirus. First subjects were dosed in a Phase 1 study in September 2023; results were expected in 2024.
- Other programs: Influenza A/B inhibitors were in preclinical development. HCV candidate CC-31244 had completed Phase 2a, and the company was seeking a development partner.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Product revenue | None reported | None reported |
| Research and development expense | $15.169 million | $12.392 million |
| General and administrative expense | $5.990 million | $5.745 million |
| Net loss | $17.984 million | $38.837 million |
| Net loss per share | $1.87 | $4.77 |
| Cash used in operating activities | $14.666 million | $21.435 million |
- At year-end, cash was $26.353 million and restricted cash was $75,000, versus cash of $37.144 million and restricted cash of $75,000 in 2022. Management said resources were expected to fund operations for at least the next 12 months; the company also cautioned that estimates depend on projected spending and other uncertainties.
- Total assets were $31.259 million, total liabilities $4.875 million, and stockholders’ equity $26.384 million. Liabilities included $1.853 million of operating lease obligations; the filing reports no conventional borrowings.
- Net loss narrowed mainly because 2022 included a $19.092 million non-cash goodwill impairment. In 2023, higher R&D spending was partly offset by a $2.6 million favorable legal-settlement line item and $640,000 of interest income. R&D expense rose as clinical programs advanced.
- Cash used in investing activities was $118,000. Financing provided $3.993 million, principally from a $4.0 million private stock placement. The placement issued 2,030,458 shares, increasing outstanding shares from 8.143 million to 10.174 million during 2023.
- Margins are not meaningful for this pre-revenue company. The filing reports no product sales or operating profitability.
Material developments, outlook and risks
- Merck elected to terminate its influenza A/B collaboration; termination became effective March 14, 2024. The agreement had offered potential milestones of up to $156 million plus royalties. Cocrystal said the compounds did not meet a specific aspect of Merck’s program.
- Cocrystal gave notice on February 28, 2024, to terminate its two KSURF license agreements, effective March 29, 2024, concluding further development under those licenses would be futile. The company stated it would continue developing its fully owned CDI-988 candidate.
- Management expects continued operating losses and negative operating cash flow over the next several years and says additional capital or partnerships may be needed. Future financing could dilute shareholders; funding may not be available on acceptable terms.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, competition from larger companies and approved therapies, viral mutations, reliance on CROs and manufacturers, intellectual-property protection, and loss of collaboration or license opportunities.
- The insurer dispute was settled in November 2023: the company received a $1.6 million court-registry refund and an additional $1.0 million payment; the parties released their claims and no further litigation remained.
- The independent auditor issued an unqualified opinion on the financial statements and reported no critical audit matters. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2023.
Most important facts for investors to verify
- Confirm actual trial status and 2024 results for CC-42344 and CDI-988. The filing contains inconsistent descriptions: elsewhere it says CC-42344’s Phase 2a trial was ongoing, but one risk-factor passage says it was completed; it also describes CDI-988 as both having completed a clinical trial and as having started Phase 1 dosing.
- Track cash use, remaining runway, and whether new financing or a partnership is required; assess potential dilution.
- Assess the development and commercial impact of the Merck and KSURF terminations, including the loss of potential Merck milestone and royalty economics.
- Review the detailed financial statements and notes for cash, lease obligations, stock compensation, related-party arrangements, and the accounting for the legal settlement.
- Verify clinical, regulatory, patent, and commercialization progress against company updates; all product candidates remain unapproved and no product-sale revenue has been generated.